RedHill Biopharma (RDHL): רווח נקי למניה ב-12 החודשים האחרונים

RDHL (RedHill Biopharma) - סמל מסחרי של החברה

The TTM net income per share for RedHill Biopharma (RDHL) is moving sideways, with 0.00 established as the baseline value. High barriers to entry are created by Talicia patents and stringent FDA oversight. The Israeli business is implementing a closed-loop water system for environmental sustainability. The current strategy relies on cost reduction and outsourcing distribution to external partners.

RDHL רווח למניה לשנה מתגלגלת RedHill (04.07.2022 - 17.11.2026)

פילוחי מדדים פיננסיים ומדדי שוק עבור RedHill (RDHL)

ניתוח כללי של החברה:RedHill Biopharma (RDHL)
מוצרים מיוצרים של RedHill Biopharma Ltd

Professional asset selection requires separating market noise from actual business performance. This metric calculates the net income per common share over the last 12 months, neutralizing the impact of the issuance volume. For RedHill Biopharma (RDHL), this calculation is critical, as generic pressure and mandatory insurer discounts directly erode margins. The TTM annual earnings per share trend clearly demonstrates the company's ability to generate value amidst weak pricing power.